 |
Vol.62 No.2 contents | Japanese/English |
 | Full Text of PDF (566K) Article in Japanese |
- Review Article -
Therapeutic Potential of Canakinumab Targeting the Inflammatory Cytokine Interleukin-1β for Non-small-cell Lung Cancer
Yasushi Goto11Department of Thoracic Oncology, National Cancer Center Hospital, Japan
Although the progression-free survival and overall survival in patients with non-small-cell lung cancer (NSCLC) have improved in recent years with the clinical introduction of immune checkpoint inhibitors, the long-term survival rates are still low. One possible reason for this is that the inflammatory cytokine interleukin-1β (IL-1β) may suppress anti-tumor immune responses by enhancing tumor-associated inflammation in the tumor microenvironment (TME). Canakinumab, a human monoclonal antibody that targets IL-1β, was shown to significantly lower the incidence and mortality rate of lung cancer in the CANTOS trial. It has been suggested that canakinumab may enhance the anti-tumor immune response and suppress tumor growth by inhibiting IL-1β activity. We herein report the association between tumor and inflammation and the role of IL-1β in the TME. We also provide an overview of ongoing clinical research of canakinumab as a promising future treatment option for NSCLC.
key words: Canakinumab, Interleukin-1β, Non-small-cell lung cancer, Pro-tumor inflammation
Received: July 12, 2021
Accepted: November 12, 2021
JJLC 62 (2): 81-89, 2022
